New cancer weapon enters human testing for Tough-to-Treat tumors
NCT ID NCT07127874
Summary
This is the first study in people testing a new experimental cancer drug called PHN-012. It aims to find a safe dose and see if it can shrink tumors in patients with advanced colon, lung, or pancreatic cancer who have no other standard treatments left. The study will enroll about 165 people to carefully monitor side effects and how the drug behaves in the body.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
PHN-012-001 Site
NOT_YET_RECRUITINGWashington D.C., District of Columbia, 20007, United States
-
PHN-012-001 Site
RECRUITINGBoston, Massachusetts, 02114, United States
-
PHN-012-001 Site
RECRUITINGDurham, North Carolina, 27710, United States
-
PHN-012-001 Site
RECRUITINGNashville, Tennessee, 37203, United States
-
PHN-012-001 Site
RECRUITINGHouston, Texas, 77030, United States
-
PHN-012-001 Site
RECRUITINGSan Antonio, Texas, 78229, United States
-
PHN-012-001 Site
RECRUITINGFairfax, Virginia, 22031, United States
Conditions
Explore the condition pages connected to this study.